Expert consensus on Tongsaimai Tablets/Capsules in treatment of peripheral vascular diseases in clinical practice.
10.19540/j.cnki.cjcmm.20211009.501
- Author:
Ye-Min CAO
1
;
Yu-Zhen WANG
1
;
Xiao-Hua PEI
2
;
Bo-Hua YANG
3
;
Cheng ZHAO
1
;
Yu-Dong FANG
1
;
Hua-Fa QUE
4
;
Yu-Feng JIANG
5
;
Xu-Ying XU
6
;
Cheng-Yong XIA
7
;
Jian-Qiang ZHANG
8
;
Chun-Hong HE
9
;
Li-Ren MA
10
Author Information
1. Shanghai Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine/Shanghai Institute of Integrated Traditional Chinese and Western Medicine and Vascular Diseases Shanghai 200086, China.
2. Xiamen Hospital of Beijing University of Chinese Medicine Xiamen 361001, China.
3. Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China.
4. Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 200032, China.
5. Special Medical Center of Strategic Support Force Beijing 100101, China.
6. Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University Beijing 100010, China.
7. Jiangsu Provincial Hospital of Traditional Chinese Medicine Nanjing 210004, China.
8. Shijiazhuang Hospital of Traditional Chinese Medicine Shijiazhuang 050051, China.
9. Luoyang Hospital of Traditional Chinese Medicine Luoyang 471000, China.
10. Pingdingshan Hospital of Traditional Chinese Medicine Pingdingshan 467000, China.
- Publication Type:Journal Article
- Keywords:
GRADE;
Tongsaimai Tablets/Capsules;
expert consensus;
peripheral vascular disease
- MeSH:
Capsules;
Consensus;
Drugs, Chinese Herbal;
Humans;
Medicine, Chinese Traditional;
Peripheral Vascular Diseases;
Tablets
- From:
China Journal of Chinese Materia Medica
2021;46(24):6568-6573
- CountryChina
- Language:Chinese
-
Abstract:
Tongsaimai Tablets/Capsules are composed of Lonicerae Japonicae Flos, Angelicae Sinensis Radix, Achyranthis Bidentatae Radix, Codonopsis Radix, Dendrobii Caulis, Astragali Radix, Scrophulariae Radix, and Glycyrrhizae Radix et Rhizoma, and are effective in promoting blood circulation, removing blood stasis, supplementing Qi, and nourishing Yin. It is widely used in the treatment of peripheral vascular diseases. With 40 years of clinical application, it has accumulated substantial research data and application experience. Its good clinical efficacy and pharmacoeconomic benefits in improving the clinical symptoms of peripheral vascular diseases have been confirmed by relevant research. Meanwhile, this drug has also been recommended by many expert consensus, guidelines, and teaching materials, serving as one of the most commonly used Chinese patent medicines in clinical practice. To further improve the understanding of the drug among clinicians and properly guide its clinical medication, the China Association of Chinese Medicine took the lead and organized experts to jointly formulate this expert consensus. Based on the questionnaire survey of clinicians and the systematic review of research literature on Tongsaimai Tablets/Capsules with clinical problems in the PICO framework, the consensus, combined with expert experience, concludes recommendations or consensus suggestions by GRADE system with the optimal evidence available through the nominal group technique. This consensus defines the indications, usage, dosage, course of treatment, medication time, combined medication, and precautions of Tongsaimai Tablets/Capsules in the treatment of peripheral vascular diseases, and explains the safety of its clinical application. It is recommended for clinicians and pharmacists in the peripheral vascular department(vascular surgery), traditional Chinese medicine surgery(general surgery), and endocrinology department of hospitals at all levels in China.
